|
 |
| |
| |
| Licensing & Royalties >> Licensing Opportunities >> Abstract Details |
|
| |
| Transgenic Mice in which the Gene for MCP-1 is Deleted |
Description of Invention:
Dr. Yoshimura has developed a transgenic mouse which does not express the chemokine MCP-1 due to a deletion of the gene for MCP-1. MCP-1 is a CC chemokine which is responsible for recruiting monocytes into sites of inflammation and cancer. Using a thioglycollate challenge as a measure of the impact of the deletion of MCP-1, MCP-1 deficient mice exhibit a 60% reduction in the number of monocytes/macrophages at 96 hours compared to wild type mice. Unlike previously generated MCP-1 deficient mice in which the expression of the neighboring gene for MCP-3 is down-regulated (our own data), the expression of MCP-3 is up-regulated in this mouse model.
Applications:
This mouse may be useful as an in vivo model for evaluating the role of MCP-1 and MCP-3 in cancer or other diseases associated with inflammation due to the accumulation of monocytes.
Inventors:
Teizo Yoshimura (NCI)
Patent Status:
HHS, Reference No. E-241-2005/0
Research Tool -- patent protection is not being pursued for this technology
Licensing Status:
Available for licensing under a Biological Materials License Agreement.
Collaborative Research Opportunity:
The National Cancer Institute, Center for Cancer Research, Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize agents useful to treat patients with inflammation or cancer. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
For Licensing Information Please Contact:
Uri Reichman Ph.D., M.B.A.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325
Room 26,
Rockville, MD 20852
United States
Email: reichmau@mail.nih.gov
Phone: 301-435-4616
Fax: 301-402-0220
Ref No: 1159
Updated: 06/2010
|
|
|
|
| |
|
|
|
|